Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle

Neuron

Volumn 81, Issue 1, 2014, Pages 49-60

  Niewoehner, Jens ^a   Bohrmann, Bernd ^b   Collin, Ludovic ^b   Urich, Eduard ^b   Sade, Hadassah ^a   Maier, Peter ^a   Rueger, Petra ^a   Stracke, JanOlaf ^a   Lau, Wilma ^a   Tissot, AlainC ^a   Loetscher, Hansruedi ^b   Ghosh, Anirvan ^b   Freskgård, Per Ola ^b  

^a Pharma Research and Early Development   (Germany)

^b Pharma Research and Early Development   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MONOCLONAL ANTIBODY 31; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY ENGINEERING; ANTIGEN BINDING; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; CELL SELECTION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; RAT; RECEPTOR BINDING; TRANSCYTOSIS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CELL LINE, TRANSFORMED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; LYSOSOMES; MACROLIDES; MICE; MICE, TRANSGENIC; MODELS, IMMUNOLOGICAL; PRESENILIN-1; PROTEIN BINDING; PROTEIN TRANSPORT; RECEPTORS, TRANSFERRIN; SINGLE-CHAIN ANTIBODIES; SUBCELLULAR FRACTIONS; TIME FACTORS; TRANSCYTOSIS;

EID: 84891804917     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2013.10.061     Document Type: Article

References (23)

1. Bohrmann B., Baumann K., Benz J., Gerber F., Huber W., Knoflach F., Messer J., Oroszlan K., Rauchenberger R., Richter W.F., et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J.Alzheimers Dis. 2012, 28:49-69.
2. Crépin R., Goenaga A.L., Jullienne B., Bougherara H., Legay C., Benihoud K., Marks J.D., Poul M.A. Development of humansingle-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas. Cancer Res. 2010, 70:5497-5506.
3. Gosk S., Vermehren C., Storm G., Moos T. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using insitu perfusion. J.Cereb. Blood Flow Metab. 2004, 24:1193-1204.
4. Kozik P., Hodson N.A., Sahlender D.A., Simecek N., Soromani C., Wu J., Collinson L.M., Robinson M.S. A human genome-wide screen for regulators of clathrin-coated vesicle formation reveals an unexpected role for the V-ATPase. Nat. Cell Biol. 2013, 15:50-60.
5. Lakadamyali M., Rust M.J., Zhuang X. Ligands for clathrin-mediated endocytosis are differentially sorted into distinct populations of early endosomes. Cell 2006, 124:997-1009.
6. LaVaute T., Smith S., Cooperman S., Iwai K., Land W., Meyron-Holtz E., Drake S.K., Miller G., Abu-Asab M., Tsokos M., et al. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 2001, 27:209-214.
7. Lesley J., Schulte R., Woods J. Modulation of transferrin receptor expression and function by anti-transferrin receptor antibodies and antibody fragments. Exp. Cell Res. 1989, 182:215-233.
8. Levy J.E., Jin O., Fujiwara Y., Kuo F., Andrews N.C. Transferrin receptor is necessary for development of erythrocytes and the nervous system. Nat. Genet. 1999, 21:396-399.
9. Liu A.P., Aguet F., Danuser G., Schmid S.L. Local clustering of transferrin receptors promotes clathrin-coated pit initiation. J.Cell Biol. 2010, 191:1381-1393.
10. Matsui T., Itoh T., Fukuda M. Small GTPase Rab12 regulates constitutive degradation of transferrin receptor. Traffic 2011, 12:1432-1443.
11. Michel V., Licon-Munoz Y., Trujillo K., Bisoffi M., Parra K.J. Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion. Int. J. Cancer 2013, 132:E1-E10.
12. Mielke M.M., Wiste H.J., Weigand S.D., Knopman D.S., Lowe V.J., Roberts R.O., Geda Y.E., Swenson-Dravis D.M., Boeve B.F., Senjem M.L., et al. Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology 2012, 79:1570-1577.
13. Navaroli D.M., Bellvé K.D., Standley C., Lifshitz L.M., Cardia J., Lambright D., Leonard D., Fogarty K.E., Corvera S. Rabenosyn-5 defines the fate of the transferrin receptor following clathrin-mediated endocytosis. Proc. Natl. Acad. Sci. USA 2012, 109:E471-E480.
14. Pardridge W.M. Drug transport across the blood-brain barrier. J.Cereb. Blood Flow Metab. 2012, 32:1959-1972.
15. Pardridge W.M., Boado R.J. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol. 2012, 503:269-292.
16. Paris-Robidas S., Emond V., Tremblay C., Soulet D., Calon F. Invivo labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor. Mol. Pharmacol. 2011, 80:32-39.
17. Poduslo J.F., Curran G.L., Berg C.T. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc. Natl. Acad. Sci. USA 1994, 91:5705-5709.
18. Richards J.G., Higgins G.A., Ouagazzal A.M., Ozmen L., Kew J.N., Bohrmann B., Malherbe P., Brockhaus M., Loetscher H., Czech C., et al. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J.Neurosci. 2003, 23:8989-9003.
19. Staquicini F.I., Ozawa M.G., Moya C.A., Driessen W.H.P., Barbu E.M., Nishimori H., Soghomonyan S., Flores L.G., Liang X., Paolillo V., et al. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J.Clin. Invest. 2011, 121:161-173.
20. Sumbria R.K., Zhou Q.H., Hui E.K., Lu J.Z., Boado R.J., Pardridge W.M. Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice. Mol. Pharm. 2013, 10:1425-1431.
21. Wang D., El-Amouri S.S., Dai M., Kuan C.Y., Hui D.Y., Brady R.O., Pan D. Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier. Proc. Natl. Acad. Sci. USA 2013, 110:2999-3004.
22. Weksler B.B., Subileua E.A., Perrière N., Charneau P., Holloway K., Leveque M., Tricoire-Leignel H., Nicotra A., Bourdoulous S., Turowski P., et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005, 19:1872-1874.
23. Yu Y.J., Zhang Y., Kenrick M., Hoyte K., Luk W., Lu Y., Atwal J., Elliott J.M., Prabhu S., Watts R.J., Dennis M.S. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med. 2011, 3:84ra44.